Summary of content
According to GIR (Global Info Research), the global revenue of oral hypoglycemic drugs (OHAs) in terms of revenue will be approximately USD million in 2023 and is expected to reach USD million in 2030, with a CAGR of % from 2024 to 2030. At the same time, the global sales volume of oral hypoglycemic drugs (OHAs) in 2023 will be about , and it is expected to reach in 2030. In 2023, the market size of China will be about one million US dollars, accounting for about % of the global market, while the North American and European markets will account for % and % respectively in the same period. In the next few years, China's CAGR will be %, while the United States and Europe will play a more important role in the Asia-Pacific region, in addition to China, the United States and Europe, Japan, South Korea, India and Southeast Asia will remain important markets that cannot be ignored.
The global pharmaceutical market is estimated to be $1.47 trillion in 2023 and is expected to grow at a CAGR of approximately 5% over the next six years. The pharmaceutical market includes both chemicals and biologics. Biologics will reach $381 billion in 2022. In comparison, the chemical pharmaceuticals market is expected to increase from $1,005.6 billion in 2018 to $1,094 billion in 2022. The pharmaceutical market is driven by the increasing demand for healthcare, advancements in pharmaceutical technology and rising prevalence of chronic diseases, and increasing pharmaceutical R&D activities and investments. However, the industry also faces various challenges, such as strict market regulation, high R&D costs, expiration of drug patents, and declining revenues. Companies need to constantly innovate and adapt to these challenges in order to remain competitive in the market. In addition, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile in responding to emerging public health needs.
This article studies the global market, sales volume and sales revenue of oral hypoglycemic drugs (OHAs) by major regions and countries, and also focuses on the analysis of the competitive situation of major manufacturers (brands) in the world, and the sales, price, revenue and market share of oral hypoglycemic drugs (OHAs).
According to the historical situation in the past five years (2019-2023), the overall scale of global oral hypoglycemic drugs (OHAs), the scale of major regions, the scale and share of major enterprises, the scale of major product classifications, and the scale of major downstream applications in the past few years are analyzed. The sizing analysis includes sales, price, revenue, and market share, among other things. In view of the development prospect of oral hypoglycemic drugs (OHAs) in the next few years, this paper predicts that by 2030, it mainly includes global and major regional sales and revenue forecasts, segmented sales volume and revenue forecasts, and sales and revenue forecasts of oral hypoglycemic drugs (OHAs) mainly used.
Based on different product types, oral hypoglycemic drugs (OHAs) are subdivided into:
Sulfonylureas
Metformin
Thiazolidinedione
α-glucosidase inhibitors
Depending on the application, this article focuses on the following areas:
Type 2 Diabetes
Type 1 Diabetes
This article focuses on the major players in the global oral hypoglycemic drugs (OHAs), including:
Pfizer
GlaxoSmithKline
Bayer
Bristol-Myers Squibb
Novonordisk
Sanofi-Aventis
Servier
Huadong Medicine
Biochemicals Wan
Double-Crane Pharmaceutical
Guangzhou Pharmaceutical
This article focuses on major regions and countries around the world, with a focus on:
North American Market (US, Canada, and Mexico)
European markets (Germany, France, the United Kingdom, Russia, Italy, and the rest of Europe)
Asia-Pacific market (China, Japan, Korea, India, Southeast Asia, Australia, etc.)
South American markets (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, UAE, Turkey, etc.)
Brief introduction of the chapter:
Chapter 1, definitions, statistical scope, product classification, application, etc., global overall size and outlook
Chapter 2, company profile, including the company's basic information, main business and main products, oral hypoglycemic drugs (OHAs) sales, revenue, price, company latest developments, etc
Chapter 3, Global Competitive Landscape Analysis, Oral Hypoglycemic Drugs (OHAs) Sales, Price, Revenue and Share of Key Companies
Chapter 4, Key Regional Sizes and Forecasts
Chapter 5, Breakdown by Product Type, Segmentation Size, and Forecast
Chapter 6, Segmentation by Application, Segmentation of Size and Forecast
Chapter 7, North America Regional Breakdown, Segmentation by Country, Product Type, and Application, Segmentation Size and Forecast
Chapter 8, Europe segmentation, by country, product type, and application, segmentation size, and forecast
Chapter 9, Asia-Pacific Segmentation, Segmentation by Region, Product Type, and Application, Segmentation Size, and Forecast
Chapter 10, South America Regional Segmentation, Segmentation by Region, Product Type, and Application, Segmentation Size, and Forecast
Chapter 11, Middle East & Africa Segmentation, Segmentation by Region, Product Type, and Application, Segmentation Size and Forecast
Chapter 12, Market dynamics, including drivers, restraints, and trends
Chapter 13, Industry Industry Chain Analysis
Chapter 14, Sales Channel Analysis
Chapter 15 Conclusions of the Report
Table of contents of the text
1 Statistical Scope
1.1 Introduction to oral hypoglycemic drugs (OHAs).
1.2 Classification of oral hypoglycemic drugs (OHAs).
1.2.1 GLOBAL MARKET COMPARISON OF ORAL HYPOGLYCEMIC DRUGS (OHAs) by product type: 2019 VS 2023 VS 2030
1.2.2 Sulfonylureas
1.2.3 Metformin
1.2.4 Thiazolidinedione
1.2.5 α-glucosidase inhibitors
1.3 Global Oral Hypoglycemic Drugs (OHAs) Major Downstream Market Analysis
1.3.1 GLOBAL ORAL HYPOGLYCEMIC DRUGS (OHAs) MAJOR DOWNSTREAM MARKET SIZE COMPARISON: 2019 VS 2023 VS 2030
1.3.2 Type 2 Diabetes
1.3.3 Type 1 Diabetes
1.4 Global oral hypoglycemic drugs (OHAs) market size and forecast
1.4.1 GLOBAL ORAL HYPOGLYCEMIC DRUGS (OHAS) MARKET SIZE AND FORECAST: 2019 VS 2023 VS 2030
1.4.2 Global Market Sales of Oral Antihyperglycemic Drugs (OHAs) (2019-2030)
1.4.3 Price trends of oral hypoglycemic drugs (OHAs) in the global market
1.5 Global market capacity analysis of oral hypoglycemic drugs (OHAs).
1.5.1 Total Oral Hypoglycemic Drugs (OHAs) Global Market Capacity (2019-2030)
1.5.2 Global Market Oral Hypoglycemic Drugs (OHAs) Production Capacity Analysis by Key Regions
2 Company Profile
2.1 Pfizer
2.1.1 Basic information of Pfizer
2.1.2 Pfizer's main business and main products
2.1.3 Pfizer Oral Antihyperglycemic Drugs (OHAs) Product Introduction
2.1.4 Pfizer Oral Hypoglycemic Drugs (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Pfizer Update
2.2 GlaxoSmithKline
2.2.1 Basic information of GlaxoSmithKline
2.2.2 GlaxoSmithKline's main business and main products
2.2.3 Product introduction of GlaxoSmithKline oral hypoglycemic drugs (OHAs).
2.2.4 GlaxoSmithKline Oral Hypoglycemic Drugs (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 GlaxoSmithKline Update
2.3 Bayer
2.3.1 Bayer基本情况
2.3.2 Bayer's main business and main products
2.3.3 Introduction to Bayer Oral Hypoglycemic Drugs (OHAs).
2.3.4 Bayer Oral Hypoglycemic Drugs (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Bayer's latest developments
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb基本情况
2.4.2 Bristol-Myers Squibb's main business and main products
2.4.3 Bristol-Myers Squibb 口服降糖药（OHAs）产品介绍
2.4.4 Bristol-Myers Squibb Oral Antihyperglycemic Drugs (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Bristol-Myers Squibb最新发展动态
- 2.5 Novonordisk
- 2.5.1 Novonordisk基本情况
2.5.2 Novonordisk's main business and main products
2.5.3 Novonordisk Oral Antihyperglycemic Drugs (OHAs) Product Introduction
2.5.4 Novonordisk Oral Antihyperglycemic Drugs (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Novonordisk Latest Developments
2.6 Sanofi-Aventis
2.6.1 Sanofi-Aventis基本情况
2.6.2 Sanofi-Aventis' main business and main products
2.6.3 Sanofi-Aventis Oral Antihyperglycemic Drugs (OHAs) Product Introduction
2.6.4 Sanofi-Aventis Oral Hypoglycemic Drugs (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Sanofi-Aventis最新发展动态
2.7 Servier
2.7.1 Servier基本情况
2.7.2 Servier's main business and main products
2.7.3 Servier Oral Antihyperglycemic Drugs (OHAs) Product Introduction
2.7.4 Servier Oral Hypoglycemic Drugs (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Servier Update
2.8 Huadong Medicine
2.8.1 Huadong Medicine基本情况
2.8.2 Huadong Medicine's main business and main products
2.8.3 Huadong Medicine Oral Hypoglycemic Drugs (OHAs) Product Introduction
2.8.4 Huadong Medicine Oral Antihyperglycemic Drugs (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Huadong Medicine's latest developments
2.9 Biochemicals
2.9.1 Wanbang Biochemicals
2.9.2 Wanbang Biopharmaceuticals' main business and main products
2.9.3 Wanbang Biopharmaceuticals Oral Hypoglycemic Drugs (OHAs) Product Introduction
2.9.4 Wanbang Biopharmaceuticals Oral Hypoglycemic Drugs (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Wanbang Biopharmaceuticals' latest developments
2.10 Double-Crane Pharmaceutical
2.10.1 Double-Crane Pharmaceutical基本情况
2.10.2 Double-Crane Pharmaceutical's main business and main products
2.10.3 Double-Crane Pharmaceutical Oral Hypoglycemic Drugs (OHAs) Product Introduction
2.10.4 Double-Crane Pharmaceutical Oral Hypoglycemic Drugs (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Double-Crane Pharmaceutical最新发展动态
2.11 Guangzhou Pharmaceutical
2.11.1 Guangzhou Pharmaceutical基本情况
2.11.2 Guangzhou Pharmaceutical's main business and main products
2.11.3 Guangzhou Pharmaceutical 口服降糖药（OHAs）产品介绍
2.11.4 Guangzhou Pharmaceutical 口服降糖药（OHAs）销量、价格、收入、毛利率及市场份额（2019-2024）
2.11.5 Guangzhou Pharmaceutical最新发展动态
3 Global Oral Hypoglycemic Drugs (OHAs) Competitive Landscape by Key Manufacturers
3.1 Global Oral Hypoglycemic Drugs (OHAs) Sales by Key Manufacturers (2019-2024)
3.2 Global Oral Hypoglycemic Drugs (OHAs) Revenue by Key Manufacturers (2019-2024)
3.3 Global Oral Hypoglycemic Drugs (OHAs) Market Position by Key Manufacturers
3.4 Global oral hypoglycemic drugs (OHAs) market concentration analysis
3.5 Product layout and regional distribution of major manufacturers of global oral hypoglycemic drugs (OHAs).
3.5.1 Regional distribution of major manufacturers of global oral hypoglycemic drugs (OHAs).
3.5.2 Global Major Manufacturers of Oral Hypoglycemic Drugs (OHAs) Product Types
3.5.3 Global Oral Hypoglycemic Drugs (OHAs) Related Business/Product Layout
3.5.4 Downstream markets and applications for oral hypoglycemic drugs (OHAs) products of major global manufacturers
3.6 New entrants to oral hypoglycemic drugs (OHAs) and expansion plans
3.7 Expansion of oral hypoglycemic drugs (OHAs) industry, mergers and acquisitions
4 Global major regional scale analysis
4.1 Global Oral Hypoglycemic Drugs (OHAs) Market Size by Major Regions
4.1.1 Global Oral Antihyperglycemic Drugs (OHAs) Sales by Key Regions (2019-2030)
4.1.2 Global Oral Hypoglycemic Drugs (OHAs) Revenue by Key Regions (2019-2030)
4.2 Oral Antihyperglycemic Drugs (OHAs) Revenue in North America Market (2019-2030)
4.3 Revenue of Oral Hypoglycemic Drugs (OHAs) in Europe Market (2019-2030)
4.4 Asia-Pacific Oral Hypoglycemic Drugs (OHAs) Revenue (2019-2030)
4.5 Revenue from Oral Hypoglycemic Drugs (OHAs) in South America Market (2019-2030)
4.6 Middle East & Africa Market Oral Antihyperglycemic Drugs (OHAs) Revenue (2019-2030)
5 Global Market Size of Oral Hypoglycemic Drugs (OHAs) by Product Type
5.1 Global Sales of Oral Hypoglycemic Drugs (OHAs) by Product Type (2019-2030)
5.2 Global Oral Hypoglycemic Drugs (OHAs) Revenue by Product Type (2019-2030)
5.3 Global Oral Hypoglycemic Drugs (OHAs) Prices by Product Type (2019-2030)
6 Global Market Market Size of Oral Hypoglycemic Drugs (OHAs) by Application
6.1 Global sales volume of oral hypoglycemic drugs (OHAs) by application (2019-2030)
6.2 Global Oral Hypoglycemic Drugs (OHAs) Revenue by Application (2019-2030)
6.3 Global Oral Hypoglycemic Drugs (OHAs) Prices by Application (2019-2030)
7 North America
7.1 North America Oral Hypoglycemic Drugs (OHAs) Sales by Product Type (2019-2030)
7.2 North America Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2030)
7.3 North America Oral Hypoglycemic Drugs (OHAs) Market Size by Major Countries
7.3.1 North America Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Major Countries (2019-2030)
7.3.2 Revenue of Oral Hypoglycemic Drugs (OHAs) by Major Countries in North America (2019-2030)
7.3.3 US Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
7.3.4 Canada Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
7.3.5 Mexico Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
8 Europe
8.1 Europe Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Product Type (2019-2030)
8.2 Europe Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2030)
8.3 Oral Hypoglycemic Drugs (OHAs) Market Size by Major European Countries
8.3.1 Sales volume of oral hypoglycemic drugs (OHAs) by major European countries (2019-2030)
8.3.2 Revenue of Oral Hypoglycemic Drugs (OHAs) in Major European Countries (2019-2030)
8.3.3 Germany Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
8.3.4 France Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
8.3.5 UK Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
8.3.6 Russia Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
8.3.7 Italy Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
9 Asia-Pacific
9.1 Asia-Pacific Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Product Type (2019-2030)
9.2 Asia-Pacific Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2030)
9.3 Asia-Pacific Oral Hypoglycemic Drugs (OHAs) Market Size
9.3.1 Asia-Pacific Sales Volume of Oral Hypoglycemic Drugs (OHAs) in Key Regions (2019-2030)
9.3.2 Asia-Pacific Revenue of Oral Hypoglycemic Drugs (OHAs) by Key Regions (2019-2030)
9.3.3 China Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast (2019-2030)
9.3.4 Japan Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
9.3.5 South Korea Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
9.3.6 India Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
9.3.7 Southeast Asia Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast (2019-2030)
9.3.8 Australia Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
10 South America
10.1 South America Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Product Type (2019-2030)
10.2 South America Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2030)
10.3 Oral Hypoglycemic Drugs (OHAs) Market Size by Major Countries in South America
10.3.1 Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Major Countries in South America (2019-2030)
10.3.2 Oral Hypoglycemic Drugs (OHAs) Revenue by Major Countries in South America (2019-2030)
10.3.3 Brazil Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
10.3.4 Argentina Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
11 Middle East and Africa
11.1 Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Product Type in Middle East & Africa (2019-2030)
11.2 Sales volume of oral hypoglycemic drugs (OHAs) by application in the Middle East and Africa (2019-2030)
11.3 Market size of oral hypoglycemic drugs (OHAs) in major countries in Middle East and Africa
11.3.1 Sales volume of oral hypoglycemic drugs (OHAs) by major countries in Middle East & Africa (2019-2030)
11.3.2 Revenue of Oral Hypoglycemic Drugs (OHAs) by Major Countries in Middle East and Africa (2019-2030)
11.3.3 Turkey Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast 2019-2030
11.3.4 Saudi Arabia Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast (2019-2030)
11.3.5 UAE Oral Hypoglycemic Drugs (OHAs) Market Size and Forecast (2019-2030)
12 Market Dynamics
12.1 Oral Hypoglycemic Drugs (OHAs) Market Drivers
12.2 Oral Hypoglycemic Drugs (OHAs) Market Restraints
12.3 Market Development Trend of Oral Hypoglycemic Drugs (OHAs).
12.4 Analysis of Porter's Five Forces Model in the Oral Hypoglycemic Drugs (OHAs) Industry
12.4.1 The current competitiveness of competitors in the industry
12.4.2 Ability of potential competitors to enter
12.4.3 Bargaining Power of Suppliers
12.4.4 Bargaining Power of the Purchaser
12.4.5 Substitution capacity of substitutes
13 Industry chain analysis
13.1 Main raw materials and suppliers of oral hypoglycemic drugs (OHAs).
13.2 Cost structure and proportion of oral hypoglycemic drugs (OHAs).
13.3 Production process of oral hypoglycemic drugs (OHAs).
13.4 Oral hypoglycemic drugs (OHAs) industry chain
14 Analysis of sales channels for oral hypoglycemic drugs (OHAs).
14.1 Sales channels of oral hypoglycemic drugs (OHAs).
14.1.1 Direct Marketing
14.1.2 Distribution
14.2 Typical distributors of oral hypoglycemic drugs (OHAs).
14.3 Typical customers of oral hypoglycemic drugs (OHAs).
15 Conclusions
16 Appendix
16.1 Research Methodology
16.2 Research Process and Data Sources
16.3 Disclaimer of Warranties
Table of Contents of Charts
Table 1. Global Market Revenue of Oral Hypoglycemic Drugs (OHAs) by Product Type, USD Million&(2019 VS 2023 VS 2030)
Table 2. GLOBAL ORAL HYPOGLYCEMIC DRUGS (OHAs) REVENUE BY APPLICATION (MILLION DOLLARS) & (2019 VS 2023 VS 2030)
Table 3. Pfizer Basics, Origins and Competitors
Table 4. Pfizer's main business and main products
Table 5. Pfizer Oral Antihyperglycemic Drugs (OHAs) Product Introduction
Table 6. Pfizer Oral Hypoglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD/Box), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. The latest developments in Pfizer
Table 8. GlaxoSmithKline basic information, origin and competitors
Table 9. GlaxoSmithKline's main business and main products
Table 10. GlaxoSmithKline Oral Antihyperglycemic Drugs (OHAs) Product Introduction
Table 11. GlaxoSmithKline Oral Hypoglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD per Box), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. The latest developments at GlaxoSmithKline
Table 13. Bayer's basic information, origin and competitors
Table 14. Bayer's main business and main products
Table 15. Bayer Oral Antihyperglycemic Drugs (OHAs) Product Introduction
Table 16. Bayer Oral Hypoglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD per Box), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. The latest developments from Bayer
表 18. Bristol-Myers Squibb基本情况、产地及竞争对手
Table 19. Bristol-Myers Squibb's main business and main products
Table 20. Bristol-Myers Squibb Oral Antihyperglycemic Drugs (OHAs) Product Introduction
Table 21. Bristol-Myers Squibb Oral Antihyperglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD Millions/Boxes), Revenue (USD Million), Gross Margin and Market Share, 2019-2024
表 22. Bristol-Myers Squibb最新发展动态
Table 23. Novonordisk Facts, Origins and Competitors
Table 24. Novonordisk's main business and main products
Table 25. Novonordisk Oral Antihyperglycemic Drugs (OHAs) Product Introduction
Table 26. Novonordisk Oral Hypoglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD per Box), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. The latest developments from Novonordisk
Table 28. Sanofi-Aventis Facts, Origins and Competitors
Table 29. Sanofi-Aventis' main business and main products
Table 30. Sanofi-Aventis Oral Antihyperglycemic Drugs (OHAs) Product Introduction
Table 31. Sanofi-Aventis Oral Antihyperglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD per Box), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
表 32. Sanofi-Aventis最新发展动态
Table 33. Servier's basic facts, origin and competitors
Table 34. Servier's main business and main products
Table 35. Servier Oral Antihyperglycemic Drugs (OHAs) Product Introduction
Table 36. Servier Oral Hypoglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD per Box), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. The latest developments at Servier
Table 38. Basic information, origin and competitors of Huadong Medicine
Table 39. Huadong Medicine's main business and main products
Table 40. Huadong Medicine Oral Hypoglycemic Drugs (OHAs) Product Introduction
Table 41. Huadong Medicine Oral Antihyperglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD/Box), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. The latest developments in Huadong Medicine
Table 43. Wanbang Biopharmaceuticals Basic Facts, Origin and Competitors
Table 44. Wanbang Biopharmaceuticals' main business and main products
Table 45. Wanbang Biopharmaceuticals Oral Antihyperglycemic Drugs (OHAs) Product Introduction
Table 46. Wanbang Biopharmaceuticals Oral Hypoglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD/Box), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. The latest developments from Wanbang Biopharmaceuticals
Table 48. Double-Crane Pharmaceutical's basic facts, origin and competitors
Table 49. Double-Crane Pharmaceutical's main business and main products
Table 50. Double-Crane Pharmaceutical Oral Hypoglycemic Drugs (OHAs) Product Introduction
Table 51. Double-Crane Pharmaceutical: Oral Hypoglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD/Box), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. The latest developments at Double-Crane Pharmaceutical
表 53. Guangzhou Pharmaceutical基本情况、产地及竞争对手
Table 54. Guangzhou Pharmaceutical's main business and main products
表 55. Guangzhou Pharmaceutical 口服降糖药（OHAs）产品介绍
Table 56. Guangzhou Pharmaceutical: Oral Hypoglycemic Drugs (OHAs) Sales Volume (Thousand Boxes), Price (USD/Box), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
表 57. Guangzhou Pharmaceutical最新发展动态
Table 58. Global Oral Hypoglycemic Drugs (OHAs) Sales by Key Manufacturers (2019-2024) & (Thousand Boxes)
Table 59. Global Oral Hypoglycemic Drugs (OHAs) Sales Share by Key Manufacturers, 2019-2024
Table 60. Global Oral Hypoglycemic Drugs (OHAs) Revenue by Key Manufacturers, 2019-2024 (USD Million)
Table 61. Global Oral Hypoglycemic Drugs (OHAs) Market Share by Major Manufacturers - 2019-2024
Table 62. Global Oral Hypoglycemic Drugs (OHAs) Market Position by Key Manufacturers (Band 1, Band 2 & Band 3)
Table 63. Global Oral Hypoglycemic Drugs (OHAs) by Major Manufacturers Headquarters and Origin Distribution
Table 64. Global Major Manufacturers of Oral Hypoglycemic Drugs (OHAs) Product Types
Table 65. The business/product layout of oral hypoglycemic drugs (OHAs) of major global manufacturers
Table 66. Downstream markets and applications for oral hypoglycemic drugs (OHAs) products of major global manufacturers
Table 67. New entrants to oral hypoglycemic drugs (OHAs) and expansion plans
Table 68. Expansion and mergers and acquisitions of oral hypoglycemic drugs (OHAs) industry
Table 69. Global Oral Hypoglycemic Drugs (OHAs) Sales by Major Regions (2019-2024) & (Thousand Boxes)
Table 70. Global Oral Hypoglycemic Drugs (OHAs) Sales by Major Regions, 2025-2030 & (Thousand Boxes)
Table 71. Global Oral Hypoglycemic Drugs (OHAs) Revenue Comparison by Key Regions: 2019 VS 2023 VS 2030 & (USD Million)
Table 72. Global Oral Hypoglycemic Drugs (OHAs) Revenue by Key Regions, 2019-2024 & (USD Million)
Table 73. Global Oral Hypoglycemic Drugs (OHAs) Revenue by Key Regions, 2025-2030 & (USD Million)
Table 74. Global Sales of Oral Antihypoglycemic Drugs (OHAs) by Product Type (2019-2024) & (Thousand Boxes)
Table 75. Global Sales of Oral Hypoglycemic Drugs (OHAs) by Product Type (2025-2030) & (Thousand Boxes)
Table 76. Global Oral Hypoglycemic Drugs (OHAs) Revenue by Product Type, 2019-2024 & (USD Million)
Table 77. Global Oral Hypoglycemic Drugs (OHAs) by Product Type, Revenue 2025-2030 & (USD Million)
Table 78. Global Oral Hypoglycemic Drugs (OHAs) by Product Type, 2019-2024 & (USD/Box)
Table 79. Global Oral Hypoglycemic Drugs (OHAs) by Product Type (2025-2030) & (USD/Box)
Table 80. Global Sales of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2024) & (Thousand Boxes)
Table 81. Global Sales of Oral Hypoglycemic Drugs (OHAs) by Application (2025-2030) & (Thousand Boxes)
Table 82. Global Oral Hypoglycemic Drugs (OHAs) Revenue by Application (2019-2024) & (USD Million)
Table 83. Global Oral Hypoglycemic Drugs (OHAs) by Application Revenue 2025-2030 & (USD Million)
Table 84. Global Oral Hypoglycemic Drugs (OHAs) by Application (2019-2024) & (USD/Box)
Table 85. Global Oral Antihyperglycemic Drugs (OHAs) by Application (2025-2030) & (USD/Box)
Table 86. North America Sales of Oral Hypoglycemic Drugs (OHAs) by Product Type (2019-2024) & (Thousand Boxes)
Table 87. North America Sales of Oral Antihyperglycemic Drugs (OHAs) by Product Type, 2025-2030 & (Thousand Boxes)
Table 88. North America Sales of Oral Antihypoglycemic Drugs (OHAs) by Application (2019-2024) & (Thousand Boxes)
Table 89. North America Sales of Oral Hypoglycemic Drugs (OHAs) by Application (2025-2030) & (Thousand Boxes)
Table 90. North America Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Major Countries (2019-2024) & (Thousand Boxes)
Table 91. North America Sales of Oral Hypoglycemic Drugs (OHAs) by Major Countries, 2025-2030 & (Thousand Boxes)
Table 92. North America Oral Hypoglycemic Drugs (OHAs) Revenue by Major Countries, 2019-2024 & (USD Million)
Table 93. North America Oral Antihyperglycemic Drugs (OHAs) Revenue by Key Countries, 2025-2030 & (USD Million)
Table 94. Europe Sales of Oral Hypoglycemic Drugs (OHAs) by Product Type (2019-2024) & (Thousand Boxes)
Table 95. Europe Sales of Oral Antihypoglycemic Drugs (OHAs) by Product Type (2025-2030) & (Thousand Boxes)
Table 96. Europe Sales of Oral Antihyperglycemic Drugs (OHAs) by Application (2019-2024) & (Thousand Boxes)
Table 97. Europe Sales of Oral Hypoglycemic Drugs (OHAs) by Application (2025-2030) & (Thousand Boxes)
Table 98. Sales of Oral Hypoglycemic Drugs (OHAs) by Major European Countries (2019-2024) & (Thousand Boxes)
Table 99. Sales of Oral Hypoglycemic Drugs (OHAs) by Major European Countries (2025-2030) & (Thousand Boxes)
Table 100. Oral Hypoglycemic Drugs (OHAs) Revenue by Major European Countries (2019-2024) & (USD Million)
Table 101. Oral Hypoglycemic Drugs (OHAs) Revenue by Major European Countries, 2025-2030 & (USD Million)
Table 102. Asia-Pacific Sales of Oral Hypoglycemic Drugs (OHAs) by Product Type (2019-2024) & (Thousand Boxes)
Table 103. Asia-Pacific Sales Volume of Oral Antihyperglycemic Drugs (OHAs) by Product Type (2025-2030) & (Thousand Boxes)
Table 104. Asia-Pacific Sales of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2024) & (Thousand Boxes)
Table 105. Asia-Pacific Sales of Oral Hypoglycemic Drugs (OHAs) by Application (2025-2030) & (Thousand Boxes)
Table 106. Asia-Pacific Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Key Regions, 2019-2024 & (Thousand Boxes)
Table 107. Asia-Pacific Sales Volume of Oral Hypoglycemic Drugs (OHAs) by Key Regions, 2025-2030 & (Thousand Boxes)
Table 108. Asia-Pacific Key Regional Oral Hypoglycemic Drugs (OHAs) Revenue, 2019-2024 & (USD Million)
Table 109. Asia-Pacific Key Regional Oral Antihyperglycemic Drugs (OHAs) Revenue, 2025-2030 & (USD Million)
Table 110. South America Sales of Oral Antihypoglycemic Drugs (OHAs) by Product Type (2019-2024) & (Thousand Boxes)
Table 111. South America Sales of Oral Hypoglycemic Drugs (OHAs) by Product Type, 2025-2030 & (Thousand Boxes)
Table 112. South America Sales of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2024) & (Thousand Boxes)
Table 113. South America Sales of Oral Hypoglycemic Drugs (OHAs) by Application (2025-2030) & (Thousand Boxes)
Table 114. Sales of Oral Antihyperglycemic Drugs (OHAs) by Major Countries in South America (2019-2024) & (Thousand Boxes)
Table 115. Sales of Oral Hypoglycemic Drugs (OHAs) by Major Countries in South America, 2025-2030 & (Thousand Boxes)
Table 116. Oral Hypoglycemic Drugs (OHAs) Revenue by Major Countries in South America, 2019-2024 & (USD Million)
Table 117. Oral Hypoglycemic Drugs (OHAs) Revenue by Major Countries in South America, 2025-2030 & (USD Million)
Table 118. Sales of Oral Antihyperglycemic Drugs (OHAs) by Product Type in Middle East & Africa (2019-2024) & (Thousand Boxes)
Table 119. Sales of Oral Antidiabetic Drugs (OHAs) by Product Type in Middle East & Africa (2025-2030) & (Thousand Boxes)
Table 120. Sales of Oral Antihyperglycemic Drugs (OHAs) by Application in Middle East & Africa (2019-2024) & (Thousand Boxes)
Table 121. Middle East & Africa Sales of Oral Hypoglycemic Drugs (OHAs) by Application (2025-2030) & (Thousand Boxes)
Table 122. Sales of Oral Hypoglycemic Drugs (OHAs) by Major Countries in Middle East & Africa (2019-2024) & (Thousand Boxes)
Table 123. Middle East & Africa Sales Volume of Oral Antihyperglycemic Drugs (OHAs) by Major Countries, 2025-2030& (Thousand Boxes)
Table 124. Middle East & Africa Oral Antihyperglycemic Drugs (OHAs) Revenue by Key Countries, 2019-2024 & (USD Million)
Table 125. Middle East & Africa Key Countries - Oral Hypoglycemic Drugs (OHAs) Revenue, 2025-2030 & (USD Million)
Table 126. The main raw material of oral hypoglycemic drugs (OHAs).
Table 127. Representative supplier of raw materials for oral hypoglycemic drugs (OHAs).
Table 128. Typical distributor of oral hypoglycemic drugs (OHAs).
Table 129. Typical customers of oral hypoglycemic drugs (OHAs).
Table of Contents of Charts
Figure 1. Oral hypoglycemic drugs (OHAs) product image
Figure 2. Global Market Revenue of Oral Hypoglycemic Drugs (OHAs) by Product Type, USD Million&(2019 VS 2023 VS 2030)
Figure 3. Sulfonylureas
Figure 4. Metformin
Figure 5. Thiazolidinedione
Figure 6. α-glucosidase inhibitors
Figure 7. Global Market Oral Hypoglycemic Drugs (OHAs) by Application Revenue (USD Million) > 2019 VS 2023 VS 2030
Figure 8. Type 2 diabetes
Figure 9. Type 1 diabetes
Figure 10. Global Oral Hypoglycemic Drugs (OHAs) Revenue (USD Million) & (Thousand Boxes): 2019 VS 2023 VS 2030
Figure 11. Global Oral Hypoglycemic Drugs (OHAs) Revenue and Forecast, 2019-2030 & (USD Million)
Figure 12. Global Market Sales of Oral Antihyperglycemic Drugs (OHAs) (2019-2030) & (Thousand Boxes)
Figure 13. Global Oral Hypoglycemic Drugs (OHAs) Price Trends - 2019-2030
Figure 14. Total Oral Hypoglycemic Drugs (OHAs) Production Capacity in Global Market (2019-2030) & (Thousand Boxes)
Figure 15. Global Market Productivity Analysis of Oral Hypoglycemic Drugs (OHAs) by Key Regions, 2023 VS 2030
Figure 16. Global Tier 1, Tier 2 & Tier 3 Oral Hypoglycemic Drugs (OHAs) Manufacturers Market Share 2023
Figure 17. Global Top 3 Oral Hypoglycemic Drugs (OHAs) Market Share 2023
Figure 18. Global Top 5 Oral Hypoglycemic Drugs (OHAs) Market Share (2023)
Figure 19. Global Oral Hypoglycemic Drugs (OHAs) Sales Share by Key Regions, 2019-2030
Figure 20. Global Oral Hypoglycemic Drugs (OHAs) Revenue Share by Key Regions, 2019-2030
Figure 21. North America Oral Antihyperglycemic Drugs (OHAs) Revenue, 2019-2030 & (USD Million)
Figure 22. Europe Market Oral Antihyperglycemic Drugs (OHAs) Revenue, 2019-2030 & (USD Million)
Figure 23. Asia-Pacific Oral Hypoglycemic Drugs (OHAs) Revenue, 2019-2030 & (USD Million)
Figure 24. South America Market Oral Antihyperglycemic Drugs (OHAs) Revenue, 2019-2030 & (USD Million)
Figure 25. Middle East & Africa Oral Hypoglycemic Drugs (OHAs) Revenue, 2019-2030 & (USD Million)
Figure 26. Global Oral Hypoglycemic Drugs (OHAs) Sales Share by Product Type, 2019-2030
Figure 27. Global Revenue Share of Oral Hypoglycemic Drugs (OHAs) by Product Type (2019-2030)
Figure 28. Global Oral Hypoglycemic Drugs (OHAs) by Product Type (2019-2030)
Figure 29. Global Sales Share of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2030)
Figure 30. Global Oral Hypoglycemic Drugs (OHAs) Revenue Share by Application (2019-2030)
Figure 31. Global Oral Antidiabetic Drugs (OHAs) by Application (2019-2030)
Figure 32. North America Oral Hypoglycemic Drugs (OHAs) Sales Share by Product Type (2019-2030)
Figure 33. North America Oral Hypoglycemic Drugs (OHAs) Sales Share by Application (2019-2030)
Figure 34. North America Sales Share of Oral Hypoglycemic Drugs (OHAs) by Key Countries, 2019-2030
Figure 35. Revenue Share of Oral Hypoglycemic Drugs (OHAs) by Key Countries in North America, 2019-2030
Figure 36. U.S. Oral Hypoglycemic Drugs (OHAs) Revenue and Growth (2019-2030) & (USD Million)
Figure 37. Canada Oral Hypoglycemic Drugs (OHAs) Revenue and Growth Rate (2019-2030) & (USD Million)
Figure 38. Mexico Oral Hypoglycemic Drugs (OHAs) Revenue and Growth (2019-2030) & (USD Million)
Figure 39. Europe Sales Share of Oral Hypoglycemic Drugs (OHAs) by Product Type, 2019-2030
Figure 40. Europe Sales Share of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2030)
Figure 41. Sales Share of Oral Hypoglycemic Drugs (OHAs) by Key Countries in Europe, 2019-2030
Figure 42. Revenue Share of Oral Hypoglycemic Drugs (OHAs) by Major European Countries, 2019-2030
Figure 43. Germany Oral Hypoglycemic Drugs (OHAs) Revenue and Growth (2019-2030) & (USD Million)
Figure 44. France Oral Antihyperglycemic Drugs (OHAs) Revenue and Growth Rate (2019-2030) & (USD Million)
Figure 45. UK Oral Hypoglycemic Drugs (OHAs) Revenue and Growth (2019-2030) & (USD Million)
Figure 46. Russia Oral Hypoglycemic Drugs (OHAs) Revenue and Growth Rate (2019-2030) & (USD Million)
Figure 47. Italy Oral Hypoglycemic Drugs (OHAs) Revenue and Growth Rate (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Sales Share of Oral Hypoglycemic Drugs (OHAs) by Product Type, 2019-2030
Figure 49. Asia-Pacific Sales Share of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2030)
Figure 50. Asia-Pacific Key Region Sales Share of Oral Hypoglycemic Drugs (OHAs) (2019-2030)
Figure 51. Asia-Pacific Key Regions - Revenue Share of Oral Hypoglycemic Drugs (OHAs) (2019-2030)
Figure 52. China's Oral Hypoglycemic Drugs (OHAs) Revenue and Growth Rate (2019-2030) & (USD Million)
Figure 53. Japan Oral Hypoglycemic Drugs (OHAs) Revenue and Growth Rate (2019-2030) & (USD Million)
Figure 54. South Korea's Oral Antidiabetic Drugs (OHAs) Revenue and Growth Rate (2019-2030) & (USD Million)
Figure 55. India Oral Hypoglycemic Drugs (OHAs) Revenue and Growth (2019-2030) & (USD Million)
Figure 56. Southeast Asia Oral Antihyperglycemic Drugs (OHAs) Revenue and Growth (2019-2030) & (USD Million)
Figure 57. Oral Hypoglycemic Drugs (OHAs) Revenue and Growth Rate in Australia, 2019-2030 & (USD Million)
Figure 58. South America Sales Share of Oral Hypoglycemic Drugs (OHAs) by Product Type (2019-2030)
Figure 59. South America Sales Share of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2030)
Figure 60. Sales Share of Oral Hypoglycemic Drugs (OHAs) by Key Countries in South America, 2019-2030
Figure 61. Revenue Share of Oral Hypoglycemic Drugs (OHAs) by Key Countries in South America, 2019-2030
Figure 62. Brazil Oral Hypoglycemic Drugs (OHAs) Revenue and Growth (2019-2030) & (USD Million)
Figure 63. Argentina Oral Hypoglycemic Drugs (OHAs) Revenue and Growth Rate (2019-2030) & (USD Million)
Figure 64. Middle East & Africa Sales Share of Oral Antidiabetic Drugs (OHAs) by Product Type (2019-2030)
Figure 65. Middle East & Africa Sales Share of Oral Hypoglycemic Drugs (OHAs) by Application (2019-2030)
Figure 66. Middle East & Africa Key Region Sales Share of Oral Hypoglycemic Drugs (OHAs) 2019-2030
Figure 67. Middle East & Africa Key Regions Revenue Share of Oral Hypoglycemic Drugs (OHAs) (2019-2030)
Figure 68. Turkey Oral Hypoglycemic Drugs (OHAs) Revenue and Growth Rate (2019-2030) & (USD Million)
Figure 69. Saudi Arabia Oral Hypoglycemic Drugs (OHAs) Revenue and Growth Rate (2019-2030) & (USD Million)
Figure 70. UAE Oral Hypoglycemic Drugs (OHAs) Revenue and Growth (2019-2030) & (USD Million)
Figure 71. Oral hypoglycemic drugs (OHAs) market drivers
Figure 72. Oral hypoglycemic drugs (OHAs) market restraints
Figure 73. Market development trend of oral hypoglycemic drugs (OHAs).
Figure 74. Porter's Five Forces Model Analysis of Oral Hypoglycemic Drugs (OHAs) Industry
Figure 75. Cost structure and proportion of oral hypoglycemic drugs (OHAs) in 2023
Figure 76. Production process of oral hypoglycemic drugs (OHAs).
Figure 77. Oral hypoglycemic drugs (OHAs) industry chain
Figure 78. Oral hypoglycemic drugs (OHAs) sales channels: direct sales and distribution channels
Figure 79. Research Methods:
Figure 80. Research process and data sources